Top-News
Quelle: - © metamorworks / iStock / Getty Images Plus / Getty Images:
Aufrufe: 242
EQS-News: Pentixapharm Releases Interim Report for the Third Quarter of 2024
Pentixapharm Holding AG
3,00
€
+3,45%
+3,45%
| EQS-News: Pentixapharm Holding AG / Key word(s): Quarterly / Interim Statement Pentixapharm Releases Interim Report for the Third Quarter of 2024 12.11.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Pentixapharm Releases Interim Report for the Third Quarter of 2024
Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Holding AG (ISIN: DE000A40AEG0), listed in the Prime Standard of the Frankfurt Stock Exchange, today published its consolidated interim report for the stub fiscal year from March 18 to September 30, 2024. Since the spin-off from Eckert & Ziegler SE, through which Pentixapharm AG and Myelo Therapeutics GmbH will be integrated into the group financial statements, was entered into the commercial register on October 2, 2024, this consolidated report includes only the figures for Pentixapharm Holding AG and does not yet contain results for either company. During the reporting period, Pentixapharm Holding AG reported a loss of €49k, attributed to other operating expenses, primarily fees and charges related to the company’s establishment, acquisition of financial assets, and the spin-off. The interim report also shows no revenue, as operational business activities will commence only after the formal spin-off of Pentixapharm AG and Myelo Therapeutics GmbH. For the 2024 consolidated annual financial statements, management anticipates a significant increase in losses in the fourth quarter due to the inclusion of Pentixapharm AG and Myelo Therapeutics GmbH from October 2, 2024, with an expected total loss of approximately –€8 million for the fiscal year. The full interim report is available on the Pentixapharm Holding AG Investor Relations website: www.pentixapharm.com/investors/reports. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
For more information, please contact: Pentixapharm Holding AG Phillip Eckert, Investor Relations ir@pentixapharm.com Tel. +49 30 94893232 www.pentixapharm.com 12.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2028371 |
| End of News | EQS News Service |
| |
2028371 12.11.2024 CET/CEST
Für dich aus unserer Redaktion zusammengestellt
Community-Beiträge zu Pentixapharm Holding AG
15.04.2025 - 19:07 Uhr
big lebowsky Zahlen waren ein Nonevent
Für 2025 sollte der Cashbestand reichen; 2026 könnte die Wandelanleihe, die von EZSE schon gezeichnet ist, gezogen werden. Ceteris paribus sollte bis Ende 2026 keine Kapitalerhöhung erfolgen. Bis dahin erwarten wir aber newsflow zu den Wirkstoffen!Quod licet Iovi non licet bovi...
11.04.2025 - 18:13 Uhr
big lebowsky Nachrichtenlos abwärts...
Am 15.04 sollen die Finanzzahlen 2024 kommen und Ausblick (?) 2025. Pentixapharm ist eine Blackbox. Finanziell sollte 2025 durchfinanziert sein und 2026 (zumindest teilweise) über die Wandelschuldverschreibung. Also warten wir auf News zu den Radiopharmaka/diagnostika. Aber der jetzige Kurs liegt 50% unter Going public. Vielleicht. ...
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.